help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dandona, P.
Right arrow Articles by Mohanty, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dandona, P.
Right arrow Articles by Mohanty, P.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 3 1141-1144
Copyright © 1999 by The Endocrine Society

Rapid Communications

Increase in Plasma Interleukin-10 Following Hydrocortisone Injection

Paresh Dandona, Ahmad Aljada, Rajesh Garg and Priya Mohanty

Division of Endocrinology, State University of New York at Buffalo; and KALEIDA Health, Buffalo, New York 14209

Address correspondence to: Paresh Dandona, Division of Endocrinology, Diabetes-Endocrinology Center of Western New York, 3 Gates Circle, Buffalo, New York 14209.

Abstract

In view of the fact that glucocorticoids have an immunosuppressive effect and the fact that interleukin-10 (IL-10) is inhibitory to T helper cell function, we have now investigated the effect of hydrocortisone on plasma IL-10 concentrations. Seven normal subjects were injected with 100 mg hydrocortisone intravenously between 8 and 9:00 a.m. Sequential blood samples were obtained prior to and 1, 2, 4, 8 and 24h after the injection. Plasma IL-10 concentrations increased significantly and consistently following the injection in all subjects. The peak increase of IL-10 occurred at 4h and the restoration to baseline by 8h. The sequential values were (mean±SD): 3.0±1.3 pg/ml at 2h, 9±4.2 pg/ml at 4h, 3.7±1.8 pg/ml at 8h and 3.7±1.4 pg/ml at 24h. The magnitude of increase was 436% of the basal at peak effect. This effect of hydrocortisone (and possibly other glucocorticoids) may contribute to the immunosuppressive effect of this drug. IL-10 may also be potentially useful in the assessment of Cushing’s Syndrome as a marker of end organ effect of glucocorticoids.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
B. M. Arafah
Hypothalamic Pituitary Adrenal Function during Critical Illness: Limitations of Current Assessment Methods
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3725 - 3745.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
L. M. Hillyer and B. Woodward
Interleukin-10 concentration determined by sandwich enzyme-linked immunosorbent assay is unrepresentative of bioactivity in murine blood
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2003; 285(6): R1514 - R1519.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Ghanim, R. Garg, A. Aljada, P. Mohanty, Y. Kumbkarni, E. Assian, W. Hamouda, and P. Dandona
Suppression of Nuclear Factor-{{kappa}}B and Stimulation of Inhibitor {{kappa}}B by Troglitazone: Evidence for an Anti-inflammatory Effect and a Potential Antiatherosclerotic Effect in the Obese
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1306 - 1312.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society